International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Special Issue 6
Original Research Article
DEEP VEIN THROMBOSIS: A SINGLE CENTRE EXPERIENCE
Published
Dec. 26, 2024
Abstract

Background:Venous thromboembolism is a significant healthcare problem, with an estimated 900,000 cases of VT and Pulmonary Embolism, causing 300,00 deaths yearly.[1]VTE is one of the most common vascular diseases associated with high morbidity rate,which is an acute event complicating 2–3/1000 hospital admissions followed by principal diagnosis.[2] Aims and objectives: • To assess the epidemiology, aetiology and treatment options for DVT. • To assess the incidence of anaemia in patients with DVT. Methodology:All patients admitted in the vascular surgery wards of SJICSR with the diagnosis of deep vein thrombosis from July 2023 to June 2024, were retrospectively analysed in terms of age, sex, risk factor, association with anaemia, laboratory factors, site affected, complications and the mode of treatment–medical/thrombolysis/IVC filter. Results:Mean age – 45.59 years, with minimum was 17 and the maximum was 84 years. Male preponderance noted. 53.7% of the cases underlying risk factor could not be identified, 11.9% patients suffered from trauma. 45.5% patients found to have anaemia. Lower limb affected more commonly than upper limb.8.2% presented with pulmonary embolism, other cases were uncomplicated. 85.8% of the cases could be managed conservatively. Conclusions: VTE is a disease of the middle age, equally distributed among male and female, lower limb affected more and conservative management remains the mainstay of treatment, commonly associated with anaemia.IVC filters – retrievable, remained the main treatment modality in those who have developed DVT following trauma, or have a scheduled surgery in the near future.

Recommended Articles
Loading Image...
Volume-5, Special Issue 6
Citations
955 Views
119 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved